University of Bradford
Leeds Teaching Hospital Trust

By specifically targeting tumour tissue, cancer selective therapies have great potential to reduce the side effects associated with conventional chemotherapy. This project will develop a platform technology utilising the unique properties of a small, non toxic entity to deliver generic oncology drugs to tumours. Academic expert input from Dr Klaus Pors and Professor Laurence Patterson from the University of Bradford, with expert clinical input from Professor Chris Twelves from Leeds NHS Foundation Trust will accelerate the project.